Clinical Trial: A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484724) titled 'A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma' on March 16.

Brief Summary: This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Advanced Esophageal Squamous Cell Carcinoma

Intervention: DRUG: JS212

JS212 will be administered every 3 weeks

DRUG: JS001

JS001 will be administered every 3 weeks

DRUG: 5-FU

5-FU will...